Pharmaceuticals and Dosing Means for Human Aging Reversal
Summary
The USPTO granted patent US12599651B2 to Intervene Immune Inc. on April 14, 2026. The patent covers pharmaceutical compositions combining human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin for reversing age-related changes including systemic inflammation, cancer risk, thymus function, immune cell populations, and epigenetic age. The patent contains 11 claims.
What changed
The USPTO granted patent US12599651B2 to Intervene Immune Inc. for a combination of medications designed to reverse multiple aspects of human aging. The protected combination includes human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin. The patent covers methods for reversing systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color changes, thymotrophic hormone levels, immune cell populations, bone marrow density, thymus structure, kidney function, and epigenetic age. The patent contains 11 claims and is classified under CPC codes A61K and C07K.
For pharmaceutical companies and biotechnology firms developing aging reversal therapies, this patent establishes intellectual property protection over a specific drug combination approach. The composition of matter patent protects the specific combination of GH, DHEA, and metformin for aging reversal applications. Companies pursuing similar combination approaches may need to either license this technology, design around the patent claims, or pursue alternative combination strategies. The FDA regulatory pathway for such combination therapies would remain separate from the IP considerations.
What to do next
- Monitor patent portfolio for competitive landscape implications
- Review IP protection strategy for aging reversal therapies
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Pharmaceuticals and dosing means for human aging reversal
Grant US12599651B2 Kind: B2 Apr 14, 2026
Assignee
INTERVENE IMMUNE INC.
Inventors
Gregory Fahy, Robert Brooke
Abstract
A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4/CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.
CPC Classifications
A61K 2300/00 A61K 31/155 A61K 31/5685 A61K 38/27 A61K 45/06 C07K 14/61
Filing Date
2023-07-03
Application No.
18346365
Claims
11
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.